Pharma Mar SA (PHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
55
About the Report
About the Report
Summary
Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.
Pharma Mar SA (PHM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Pharma Mar SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13
Merger 14
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14
Licensing Agreements 15
Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16
Pharma Mar Enters into Licensing Agreement with Megapharm 17
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19
Eczacibasi Enters into Licensing Agreement with Pharma Mar 20
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24
TTY Biopharm Enters into Licensing Agreement with PharmaMar 25
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27
Equity Offering 28
Pharma Mar Plans to Raise Funds through Public Offering of ADS 28
Pharma Mar SA-Key Competitors 29
Pharma Mar SA-Key Employees 30
Pharma Mar SA-Locations And Subsidiaries 31
Head Office 31
Other Locations & Subsidiaries 31
Recent Developments 33
Financial Announcements 33
Oct 30, 2018: PharmaMar reports net profit of EUR5 million at the end of the third quarter of 2018 33
Jul 26, 2018: PharmaMar group obtained a net profit of EUR3 million in the first half of 2018 34
Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results 35
Feb 28, 2018: PharmaMar group announces 2017 earnings results 36
Oct 24, 2017: Pharma Mar group revenues totalled EUR140 million in the first nine months of the year 37
Jul 26, 2017: Pharma Mar group reports first half financial results 38
Apr 27, 2017: PharmaMar Group reports EUR45.5 million in revenues (+8%) 39
Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 40
Corporate Communications 42
Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development 42
Government and Public Interest 43
Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 43
Product News 45
06/16/2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 45
04/27/2017: PharmaMar demonstrates its progress in R&D in New York 46
04/04/2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 47
Clinical Trials 48
Sep 19, 2017: PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors 48
Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 49
May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 50
Other Significant Developments 51
Jul 30, 2018: Immedica-a platform for pan-European niche specialty pharma launch, commercialization and distribution services 51
Jun 28, 2018: PharmaMar's 2017 Group Annual General Shareholder's' meeting 52
Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 54
Appendix 55
Methodology 55
About GlobalData 55
Contact Us 55
Disclaimer 55
List of Figure
List of Figures
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Pharma Mar SA, Deals By Therapy Area, 2012 to YTD 2018 9
Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10
Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12
Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13
Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14
Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15
Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16
Pharma Mar Enters into Licensing Agreement with Megapharm 17
Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18
Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19
Eczacibasi Enters into Licensing Agreement with Pharma Mar 20
Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21
Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23
Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24
TTY Biopharm Enters into Licensing Agreement with PharmaMar 25
PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26
PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27
Pharma Mar Plans to Raise Funds through Public Offering of ADS 28
Pharma Mar SA, Key Competitors 29
Pharma Mar SA, Key Employees 30
Pharma Mar SA, Subsidiaries 31
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.